Skip to main content
SpringerLink
Log in

Antibody Therapy in Non-Hodgkin’s Lymphoma: The Role of Rituximab, 90Y-Ibritumomab Tiuxetan, and Alemtuzumab

  • Chapter
Book cover Targeted Therapies in Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 176))

Abstract

Targeting cancer cells with monoclonal antibodies has become an indispensable part of modern treatment against hematologic malignancies. The excitement of the first successful experimental results could be confirmed by large multicenter trials, thus paving the way for new approaches in first-line, relapse, and maintenance therapy. Three antibodies—rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab—are in clinical use worldwide and are reviewed in this chapter with a focus on practical information and fundamental principles of antibody-based therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ansell SM, Schilder RJ, Pieslor PC, et al (2004) Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin’s lymphoma: a review of the literature. Clin Lymphoma 5:202–204

    PubMed  Google Scholar 

  • Berinstein NL, Grillo-López AJ, White CA, et al (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 9:995–1001

    Article  PubMed  CAS  Google Scholar 

  • Cartron G, Watier H, Golay J, et al (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635–2642

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD (2005) The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19:309–322

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD (2006) Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 55:188–196

    Article  PubMed  CAS  Google Scholar 

  • Coiffier B (2004) Effective immunochemotherapy for aggressive non-Hodgkin’s lymphoma. Semin Oncol 31[Suppl 2]:7–11

    Article  PubMed  CAS  Google Scholar 

  • Coiffier B, Haioun C, Ketterer N, et al (1998) Rituximab (anti CD-20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 92:1927–1932

    PubMed  CAS  Google Scholar 

  • Coiffier B, Lepage E, Briere J, et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  PubMed  CAS  Google Scholar 

  • Czuczman M, Emmanouilides C, Witzig T, et al (2002) Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkins lymphoma. Proc Am Soc Clin Oncol 21:abstr 1062

    Google Scholar 

  • DeMonaco N, Wu M, Osborn J (2005) Phase II trial of abbreviated CHOP-rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood 106:abstr 2449

    Google Scholar 

  • Ely P, Stearns D, Zaki B, et al (2005) Successful PBSC mobilization, collection, transplantation and engraftment after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma (NHL). Blood 106:abstr 5517

    Google Scholar 

  • Emmanouilides C, Murray J, Vo K, et al (2003) Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkins lymphoma (NHL): results with second-line therapy. Blood 102:abst 4949

    Google Scholar 

  • Feugier P, Van Hoof A, Sebban C, et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126

    Article  PubMed  CAS  Google Scholar 

  • Fietz T, Rieger K, Schmittel A, et al (2004) Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 5:451–452

    Article  PubMed  CAS  Google Scholar 

  • Fietz T, Uharek L, Gentilini C, et al (2006) Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 47:59–63

    Article  PubMed  CAS  Google Scholar 

  • Fisher RI, Gaynor ER, Dahlberg S, et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for ad vanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  • Fisher RI, LeBlanc M, Press OW, et al (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447–8452

    Article  PubMed  CAS  Google Scholar 

  • Ghielmini M, Schmitz SF, Cogliatti SB, et al (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416–4423

    Article  PubMed  CAS  Google Scholar 

  • Ghielmini M, Schmitz SF, Cogliatti S, et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705–711

    Article  PubMed  CAS  Google Scholar 

  • Gordan LN, Grow WB, Pusateri A, et al (2005) Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. Clin Oncol 23:1096–1102

    Article  CAS  Google Scholar 

  • Gordon LI, Witzig T, Molina A, et al (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5:98–101

    PubMed  CAS  Google Scholar 

  • Groot MT, Lugtenburg PJ, Hornberger J, et al (2005) Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 74:194–202

    Article  PubMed  CAS  Google Scholar 

  • Habermann TM, Weller E, Morrison VA, et al (2004) Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood 104:abstr 127

    Google Scholar 

  • Hainsworth JD, Litchy S, Burris HA 3rd, et al (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 20:4261–4267

    Article  PubMed  CAS  Google Scholar 

  • Hainsworth JD, Litchy S, Shaffer DW, et al (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma— a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088–1095

    Article  PubMed  CAS  Google Scholar 

  • Hale G, Waldmann H (2000) From laboratory to clinic: the story of CAMPATH-1. Methods Mol Med 40:243–266

    CAS  Google Scholar 

  • Herold M, Pasold R, Srock S, et al (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 104:abstr 584

    Google Scholar 

  • Hiddemann W, Kneba M, Dreyling M, et al (2005a) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732

    Article  PubMed  CAS  Google Scholar 

  • Hiddemann W, Forstpointner R, Dreyling M, et al (2005b) Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 23:Abstr 6527

    Google Scholar 

  • Hieke K, Pasold R, Neser S, et al (2004) Cost evaluation of rituximab plus MCP vs. MCP alone in advanced stage indolent non-Hodgkin’s-lymphoma based on a randomized controlled multicenter trial. Blood 104:Abstr 87

    Google Scholar 

  • Huhn D, von Schilling C, Wilhelm M, et al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326–1331

    Article  PubMed  CAS  Google Scholar 

  • Keating MJ, O’Brien S, Albitar M, et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Clin Oncol 23:4079–4088

    Article  CAS  Google Scholar 

  • Khouri IF, Saliba RM, Hosing C, et al (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin’s lymphomas. J Clin Oncol 23:2240–2247

    Article  PubMed  CAS  Google Scholar 

  • Kiewe P, Jahnke K, Maza S, et al (2006) Yttrium-90-ibritumomab tiuxetan (Zevalin) for primary CNS lymphoma: encouraging response data in an innovative prospective therapeutic trial. 44th Annual Convention of the German Society for Nuclear Medicine. Schattauer Verlag, Stuttgart, V133

    Google Scholar 

  • Liu N, Keating M, Albitar M, et al (2003) Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. Blood 102:Abstr 2498

    Google Scholar 

  • Lundin J, Kimby E, Bjorkholm M, et al (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100:768–773

    Article  PubMed  CAS  Google Scholar 

  • Maloney DG (2005) Treatment of follicular non-Hodgkin’s lymphoma. Curr Hematol Rep 4:39–45

    PubMed  CAS  Google Scholar 

  • Marcus R, Imrie K, Belch A, et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423

    Article  PubMed  CAS  Google Scholar 

  • Micallef IN (2004) Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin’s lymphoma. Clin Lymphoma 5[Suppl 1]:27–32

    Article  Google Scholar 

  • Moreton P, Kennedy B, Lucas G, et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Clin Oncol 23:2971–2979

    Article  CAS  Google Scholar 

  • O’Brien S, Kantarjian H, Thomas DA, et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165–2170

    PubMed  CAS  Google Scholar 

  • Orina JN, Moore S, Lechowicz M, et al (2005) Systematic review and meta-analysis of radioimmunotherapy regimens in patients with relapsed follicular and transformed non Hodgkins lymphomas. Blood 106:Abstr 3113

    Google Scholar 

  • Pfreundschuh M, Truemper L, Gill D, et al (2004) First analysis of the completed Mabthera International (Mint) Trial in Young Patients with Low-Risk Diffuse Large B-Cell Lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identifi-cation of a very favorable subgroup with IPI=O and no bulky disease. Blood 104:Abstr 157

    Google Scholar 

  • Pfreundschuh M, Kloess M, Schmits R, et al (2005) Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 106:Abstr 13

    Google Scholar 

  • Rieger K, Von Grunhagen U, Fietz T, et al (2004) Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia—change of regimen needed? Leuk Lymphoma 45:345–349

    Article  PubMed  CAS  Google Scholar 

  • Robak T (2005) Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 19:9–22

    Article  PubMed  CAS  Google Scholar 

  • Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54:11–29

    PubMed  CAS  Google Scholar 

  • Theuer CP, Leigh BR, Multani PS, et al (2004) Radioimmunotherapy of non-Hodgkin’s lymphoma: clinical development of the Zevalin regimen. Biotechnol Annu Rev 10:265–295

    PubMed  CAS  Google Scholar 

  • Thieblemont C, Boufia F, Hornez E, et al (2004) Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-CLL/SLL. Leuk Lymphoma 45:711–714

    Article  PubMed  CAS  Google Scholar 

  • Thieblemont C, Roch H, Boubacari AT, et al (2005) Maintenance alemtuzumab in refractory B-cell chronic lymphocytic leukemia patients: updated data. Blood 106:Abstr 5032

    Google Scholar 

  • Van Oers M, Glabbeke M, Teodorovic I, et al (2004) Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma:a phase III randomized intergroup clinical trial. Blood 104:Abstr 586

    Google Scholar 

  • Wendtner CM, Ritgen M, Schweighofer CD, et al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093–1101

    Article  PubMed  CAS  Google Scholar 

  • Witzig TE, Gordon LI, Cabanillas F, et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20: 2453–2463

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology, Oncology and Transfusion Medicine, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    Thomas Fietz MD

  2. Medizinische Klinik III (Hematology, Oncology and Transfusion Medicine), Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    Eckhard Thiel MD PhD

Authors
  1. Thomas Fietz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eckhard Thiel MD PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pathologie, Charité Humboldt-Universität zu Berlin, Schumanstr. 20-21, 10117, Berlin, Germany

    Manfred Dietel

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fietz, T., Thiel, E. (2007). Antibody Therapy in Non-Hodgkin’s Lymphoma: The Role of Rituximab, 90Y-Ibritumomab Tiuxetan, and Alemtuzumab. In: Dietel, M. (eds) Targeted Therapies in Cancer. Recent Results in Cancer Research, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-46091-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-46091-6_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-46090-9

  • Online ISBN: 978-3-540-46091-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation